CSOWM CERTIFICATION EVALUATION
2026 STUDY GUIDE QUESTIONS AND
ANSWERS
◉ Management of BMI >/=30
Answer: Diet, exercise, behavior + pharmacotherapy
◉ Management of BMI >/= 27 + comorbidity
Answer: Diet, exercise, behavior + pharmacotherapy
◉ Management of BMI >/=35 + cormorbidity
Answer: Bariatric surgery
◉ Management of BMI >/=40
Answer: Bariatric surgery
◉ Co-morbidities
Answer: T2DM
HTN
OSA and other respiratory disorders
,NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
◉ Medication assessment
Answer: Every month x3 months, then every 3 months
◉ Effective weight loss %
Answer: >/=5% in 3 months
◉ Avoid these wt loss meds with HTN/HD
Answer: Sympathomimetics (phentermine/diethylproprion)
◉ Avoid these wt loss medications with CVD
Answer: Sypathomimetics
◉ T2DM treatment + medications to support weight loss
Answer: GLP-1 analog (mitigates associated weight gain due to
insulin) or SGLT-2 inhibitors + metformin. If using insulin,
recommend basal instead of combo
,◉ Drugs that induce weight gain
Answer: Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
◉ Hormonal signals for appetite
Answer: CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
, ◉ GLP-1
Answer: Secreted in response to glucose and promotes insulin
release from pancreas and satiety
◉ Ghrelin
Answer: produced in the stomach, orexigenic
◉ Leptin
Answer: proportional to fat mass, anorexigenic
Inhibits appetite
◉ PYY
Answer: Ileum and colon, anorexigenic
◉ CCK
Answer: duodenum, anorexigenic
◉ Insulin
Answer: Pancreas, anorexigenic
2026 STUDY GUIDE QUESTIONS AND
ANSWERS
◉ Management of BMI >/=30
Answer: Diet, exercise, behavior + pharmacotherapy
◉ Management of BMI >/= 27 + comorbidity
Answer: Diet, exercise, behavior + pharmacotherapy
◉ Management of BMI >/=35 + cormorbidity
Answer: Bariatric surgery
◉ Management of BMI >/=40
Answer: Bariatric surgery
◉ Co-morbidities
Answer: T2DM
HTN
OSA and other respiratory disorders
,NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
◉ Medication assessment
Answer: Every month x3 months, then every 3 months
◉ Effective weight loss %
Answer: >/=5% in 3 months
◉ Avoid these wt loss meds with HTN/HD
Answer: Sympathomimetics (phentermine/diethylproprion)
◉ Avoid these wt loss medications with CVD
Answer: Sypathomimetics
◉ T2DM treatment + medications to support weight loss
Answer: GLP-1 analog (mitigates associated weight gain due to
insulin) or SGLT-2 inhibitors + metformin. If using insulin,
recommend basal instead of combo
,◉ Drugs that induce weight gain
Answer: Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
◉ Hormonal signals for appetite
Answer: CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
Liver- glucagon
, ◉ GLP-1
Answer: Secreted in response to glucose and promotes insulin
release from pancreas and satiety
◉ Ghrelin
Answer: produced in the stomach, orexigenic
◉ Leptin
Answer: proportional to fat mass, anorexigenic
Inhibits appetite
◉ PYY
Answer: Ileum and colon, anorexigenic
◉ CCK
Answer: duodenum, anorexigenic
◉ Insulin
Answer: Pancreas, anorexigenic
